Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of belimumab plus rituximab in adult SLE
2016-003050-32Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Belimumab + rituximab with Placebo (2 arms). Primary endpoint: Disease control by SLEDAI-2K. Started Jun 2017; status: completed.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-003050-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003050-32.